Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Aptevo Therapeutics Inc
APVO
Healthcare
Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax...
+ azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:APVO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
Next
(0)
•••
PressRelease
X
Post by
PressRelease
on Oct 08, 2025 8:20am
New Press Release - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter
SEATTLE, WASHINGTON / ACCESS Newswire / October 8, 2025 / Aptevo Therapeutics ("Aptevo" or the "Company") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific and trispecific immuno-oncology therapeutics, today announced its participation in upcoming key financial...
read article.
(242)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Oct 07, 2025 8:50am
Buy buddy buy.
Otherwise FOMO
(242)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Sep 18, 2025 6:34am
Buy buddy buy because it's taking off this morning.
Otherwise FOMO for you fellas out there today anyway so good luck to all of you guys
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 18, 2025 5:39am
APVO....sold all into the 2nd rally to $2.65
Back to bed for me Thx for the $'s
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 18, 2025 4:48am
APVO....up in PM open....Traded at $2.65
C what happens during Reg hours open
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 17, 2025 8:07pm
APVO.... Steven A. Cohen filed a SEC 13G today
Read this Bio .... Steven A. Cohen - Point72 Here is the SEC 13G that was filed..... https://www.sec.gov/Archives/edgar/data/1671584/000090266425004113/xslSCHEDULE_13G_X01/primary_doc.xml
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 17, 2025 6:54pm
APVO.....It traded a chit ton a day ago..like 114 mil shares
Hardly any came back....just an observation A Break of $2.13 would be meaningful Currently trading at $2.03
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 17, 2025 6:49pm
APVO....should a coulda.... didn't
Now over $2
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 17, 2025 5:58pm
APVO....sold all into the rally over $1.95
Cheers !
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 17, 2025 5:53pm
APVO....big bounce off the L.O.D during AH
Now over $1.80
(434)
•••
Iseneschal
X
Comment by
Iseneschal
on Sep 16, 2025 9:56am
RE:APVO.....up on NR
Lots of Volume.....Price Action is Meh ! No position
(434)
•••
Iseneschal
X
Post by
Iseneschal
on Sep 16, 2025 9:43am
APVO.....up on NR
On watch...$2.30
(242)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Sep 16, 2025 9:29am
Buy buddy buy because it is going up this morning.
This stock is signalling strength to the upside for shareholders today anyway
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 20, 2025 11:30am
New Press Release - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today announced the closing of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Jun 20, 2025 8:55am
New Press Release - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
Mipletamig-driven clinical validation of the CRIS-7 derived CD3-binding domain underpins Aptevo's expansion from hematologic to solid tumorsNew candidate APVO455 targets Nectin-4+ cancers, joins mipletamig (AML) and APVO442 (prostate) in Aptevo's tumor-directed CD3 suiteSEATTLE, WASHINGTON...
read article.
Prev
1
2
3
4
5
6
7
8
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.